Soligenix Inc. (SNGX) Expected to Post Earnings of -$0.32 Per Share

Wall Street analysts expect that Soligenix Inc. (NASDAQ:SNGX) will post earnings per share of ($0.32) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Soligenix’s earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.41). Soligenix posted earnings per share of ($0.17) in the same quarter last year, which indicates a negative year over year growth rate of 88.2%. The company is scheduled to report its next quarterly earnings report on Monday, March 26th.

On average, analysts expect that Soligenix will report full-year earnings of ($1.28) per share for the current fiscal year, with EPS estimates ranging from ($1.43) to ($1.10). For the next financial year, analysts expect that the firm will report earnings of ($1.51) per share, with EPS estimates ranging from ($2.00) to ($1.01). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Soligenix.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.15. The firm had revenue of $1.82 million during the quarter, compared to the consensus estimate of $1.36 million. Soligenix had a negative net margin of 90.93% and a negative return on equity of 112.81%.

SNGX has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $5.50 price target (down previously from $11.00) on shares of Soligenix in a research note on Monday, November 6th. Maxim Group set a $5.00 price target on shares of Soligenix and gave the company a “buy” rating in a research note on Tuesday, October 31st.

TRADEMARK VIOLATION WARNING: “Soligenix Inc. (SNGX) Expected to Post Earnings of -$0.32 Per Share” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at

Soligenix (NASDAQ:SNGX) traded down $0.17 during mid-day trading on Monday, hitting $2.15. 118,400 shares of the stock traded hands, compared to its average volume of 272,566. Soligenix has a 12-month low of $1.74 and a 12-month high of $5.08.

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Get a free copy of the Zacks research report on Soligenix (SNGX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply